NCT02907073 · REGISTRY CONDITION SEARCH

Positron Emission Tomography (PET) Imaging Studies With NIS Reporter

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: TERMINATED
Registry last update: 2019-05-17

The goal of this proposal is to perform first-in-man evaluation of and experimental imaging agent F-18 tetrafluoroborate (BF4) or (TFB).

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Evaluation of Tissue Distribution of F-18 BF4 in Healthy Volunteers

→

outcome · POSTED

Amount of Imaging Agent in Tumor (Uptake) in Myeloma and Endometrial Cancer Patients

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Four male and four female healthy volunteers, greater than 21 years of age. * Subjects must provide written informed consent. * Willingness to provide all biological specimens as required by the protocol Exclusion Criteria: Volunteers with any of the following are ineligible to enroll in this study: * Have currently clinically significant cancer, neurologic, hepatic, renal, pulmonary, metabolic, or endocrine disturbances, especially thyroid disease; * Current clinically significant cardiovascular disease. Clinically significant cardiovascular disease usually includes one or more of the following: 1. cardiac surgery or myocardial infarction within the last 6 months; 2. unstable angina; 3. coronary artery disease that required a change in medication within the last 3 months; 4. decompensated congestive heart failure; 5. significant cardiac arrhythmia or conduction disturbance, particularly those resulting in atrial or ventricular fibrillation, or causing syncope, near syncope, or other alterations in mental status; 6. severe mitral or aortic valvular disease; 7. uncontrolled high blood pressure; 8. congenital heart disease; * History of drug or alcohol abuse within the last year, or prior prolonged history of abuse; * Clinically significant infectious disease, including AIDS or HIV infection or previous positive test for hepatitis B, hepatitis C, HIV-1, or HIV-2; * Women of childbearing potential must not be pregnant (negative urine Human Chorionic Gonadotropin (β-HCG) at the time of screen) or lactating over the course of the study. A commercial urine dipstick test will be performed within 48 hours prior to injection of \[18F\]BF4 unless the screening urine pregnancy test falls within 48 hours of injection. * Volunteers who, in the opinion of the investigator, are otherwise unsuitable for a study of this type; * History of severe drug allergy or hypersensitivity; or * Volunteers who had received an investigational medication within the last 30 days or who have participated in a clinical trial with any experimental medication or radiopharmaceutical in the last 30 days. Additionally, the time between the last dose of the previous experimental medication and enrollment (completion of screening assessments) must be at least equal to 5 times the terminal half-life of the previous experimental medication. * Volunteers who are taking drugs with narrow therapeutic windows, such as theophylline, or warfarin, heparin and other anticoagulant therapies
healthy Volunteers: true
minimum Age: 21 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
At the study visit, healthy subjects will have an initial physical exam, urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration and blood sampling. Vital signs, and blood samples will be obtained. Subjects will receive an infusion \[18F\]BF4 over 1 minute and PET imaging will begin. Three (3) PET/CT scanning procedures will be performed over a period of approximately 4 hours with two rest breaks in between. Venous blood samples for clinical laboratory tests will be taken before radiotracer administration and at 1.5 hours post-administration of radiotracer. In addition, venous blood samples will be taken during the PET/CT scans to determine blood pharmacokinetics and metabolite evaluation. Physical exam will be repeated at the end of the study.
intervention Names
Drug: BF4
label
Healthy Volunteers
type
EXPERIMENTAL
description
For cancer patients undergoing virus treatments, subjects will undergo \[18F\]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of \[18F\]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of \[18F\]BF4 in up to three myeloma patients when the site is accessible for biopsy.
intervention Names
Drug: BF4
label
Myeloma patients
type
EXPERIMENTAL
description
For cancer patients undergoing virus treatments, subjects will undergo \[18F\]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of \[18F\]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of \[18F\]BF4 in up to three endometrial cancer patients when the site is accessible for biopsy.
intervention Names
Drug: BF4
label
Endometrial cancer patients
type
EXPERIMENTAL

interventions

arm Group Labels
Endometrial cancer patients
Healthy Volunteers
Myeloma patients
description
Single IV dose of 9-11 millicurie (mCi) sodium \[Fluorine-18\] radiolabeled B4\^F
name
BF4
other Names
Tetrafluoroborate, TFB
type
DRUG

Study design

allocation

NON_RANDOMIZED

intervention Model

FACTORIAL

masking Info

masking: NONE

primary Purpose

DIAGNOSTIC

Enrollment

count: 8
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
F-18 BF4 concentrations in major tissues (e.g., heart, blood pool, lung, liver, thyroid, stomach, kidney, brain, muscle) will be evaluated from the PET images from 0-240 minutes post-administration. Results will be used to compute radiation dosimetry estimates.
measure
Evaluation of Tissue Distribution of F-18 BF4 in Healthy Volunteers
time Frame
0-240 minutes

secondary Outcomes

description
Areas of positive uptake within tumor, relative to background, measured by Standardized Update Value (SUV). PET SUV is tissue concentration/injected dose/body weight in grams.
measure
Amount of Imaging Agent in Tumor (Uptake) in Myeloma and Endometrial Cancer Patients
time Frame
Baseline, Day 9

Full study description

brief Summary: The goal of this proposal is to perform first-in-man evaluation of and experimental imaging agent F-18 tetrafluoroborate (BF4) or (TFB).
detailed Description: F-18 tetrafluoroborate (BF4) or (TFB) is being used as a PET (Positron Emission Tomography) imaging biomarker for expression of the human sodium/iodide symporter (hNIS) in tissues. Imaging of functional hNIS activity in tissues with \[18F\]BF4 is anticipated to provide superior sensitivity and image quality to I-123 or Tc-99m SPECT for monitoring hNIS transduction effected by viral therapies. The proposed work is designed to 1) evaluate its safety, biodistribution, metabolism and radiation dosimetry characteristics in 8 healthy human volunteers and 2) evaluate the imaging feasibility in comparison with I-123 or Tc-99m SPECT of hNIS expression in a) 10 myeloma patients treated with Edmonston Measles virus-NIS (MV-NIS) and b) 10 endometrial cancer patients treated with vesicular stomatitis virus engineered to express human interferon and NIS (VSV-hINF-NIS). This data will be necessary to support future regulatory submissions.

Source references